UroGen Pharma
Highly Engaged Employees
Manufacturing · New Jersey, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
400 Alexander Park Fl 4, Princeton, New ...Phone Number
(646) 768-9780Website
www.urogen.comRevenue
$140.5 MillionStock Symbol
URGNIndustry
About UroGen Pharma
UroGen Pharma Org Chart
Is UroGen Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if UroGen Pharma is spiking on competitors!
Earning: See what the market has to say on UroGen Pharma recently announced quarterly report
UroGen Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when UroGen Pharma launches new products
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once UroGen Pharma has new funding data
Check if UroGen Pharma has recently received funding, and reach out quickly before it becomes old news!
Click to see if UroGen Pharma had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at UroGen Pharma
Recommended Actions
Find VP level buyers at UroGen Pharma
Find 2 more new buyers
Compare Similar Companies to UroGen Pharma
Compare insights from companies similar to UroGen Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
UroGen Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
UroGen Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about UroGen Pharma.
UroGen Pharma financials insights
Gather financial insights about UroGen Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Private Equity
$75M
Other Financing Round
$120M
UroGen Pharma Tech Stack
A closer look at the technologies used by UroGen Pharma
Most Recent Scoops
UroGen Pharma News & Media
UroGen Pharma Ltd. (URGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
UroGen Pharma Ltd. (URGN) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 10, 2026 8:40 AM EDTCompany ParticipantsElizabeth Barrett -...UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 21 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of JELMYTO® (mitomycin) for pyelocalyceal solution and ZUSDURITM (mitomycin) fUroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution
UroGen settlement agreement with Teva protects JELMYTO patentUroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
PRINCETON, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference to take place on June 8-10, 2026.
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding UroGen Pharma
UroGen Pharma is a biopharmaceutical company focused on developing innovative therapeutic solutions for specialty cancers and urologic diseases. The company operates with a core mission to address unmet medical needs in areas where current treatment options remain limited, working to expand the arsenal of therapies available to patients facing comp... Read More